<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Ang Chan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew Kulke, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas E Clancy, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tracy Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H688217"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that are thought to arise from neuroendocrine cells and their precursors located throughout the body. These tumors are characterized by variable but most often indolent biologic behavior. They are also classically characterized by their ability to secrete peptides resulting in distinctive hormonal syndromes.</p><p class="headingAnchor" id="H1970242"><span class="h2">Classification and nomenclature</span><span class="headingEndMark"> — </span>Neuroendocrine neoplasms can arise at different sites within the body and are classified according to their histologic features. While there are differences in terminology and grading depending on site of origin, all commonly used classification systems reflect a basic separation between more indolent, well-differentiated NETs (which in the digestive system were previously referred to as carcinoid tumors and pancreatic neuroendocrine [islet cell] tumors) and far more aggressive, poorly differentiated neuroendocrine carcinomas (which behave clinically more like small cell carcinoma of the lung). (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Classification and nomenclature'</a>.)</p><p>This topic review will cover local treatment options for patients with well-differentiated metastatic gastroenteropancreatic NETs. Systemic treatment options to control tumor growth and/or symptoms of hormone hypersecretion from gastroenteropancreatic NETs and the treatment of poorly differentiated neuroendocrine carcinomas are discussed elsewhere, as are the clinical presentation, imaging, and biochemical monitoring for patients with advanced gastroenteropancreatic NETs; pathology and classification of gastroenteropancreatic NETs; clinical features of NETs; diagnosis of carcinoid syndrome and tumor localization; treatment of early stage NETs; lung NETs; localization and treatment of pancreatic NETs; evaluation and management of NETs of unknown primary site; management of symptoms of the carcinoid syndrome; carcinoid heart disease; and functioning pancreatic NETs:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2187.html" rel="external">"Insulinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H1970317"><span class="h1">NATURAL HISTORY AND TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>NETs are a heterogeneous group of malignancies characterized by variable but most often indolent biologic behavior. Clinical behavior and prognosis correlate closely with histologic differentiation and grade. The World Health Organization (WHO) classifies well-differentiated gastroenteropancreatic NETs into low-grade (G1), intermediate-grade (G2), and high-grade (G3) categories based on histologic appearance and proliferative rate (as assessed by mitotic count and/or Ki-67 labeling index)  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Poorly differentiated neuroendocrine carcinomas are high-grade neoplasms that can be further classified as small cell or large cell type neuroendocrine carcinomas. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p>Among patients with G1 or G2 histology and distant disease, survival is highly variable and can depend on other factors, including primary tumor location. As an example, among patients with advanced NETs, outcome is worst for patients with lung and colon (other than cecum) primaries (median survival 17 and 7 months, respectively) and is most favorable for tumors arising in the jejunum, ileum, and cecum (median survival 55 to 65 months) [<a href="#rid2">2</a>]. This wide difference in natural history complicates the comparative assessment of benefit from individual therapies.</p><p>Patients with metastases from a gastroenteropancreatic NET may become symptomatic from hormone hypersecretion rather than from tumor bulk. Approximately 10 to 30 percent of pancreatic NETs secrete hormones resulting in clinical syndromes; additionally, patients with midgut (small bowel or appendiceal) NETs may develop carcinoid syndrome, typically after development of hepatic metastases and entry of vasoactive substances, such as serotonin, into the systemic circulation. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p>Symptoms of hormonal excess from functional NETs can often be well controlled with somatostatin analogs, such as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> or <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a>. Similarly, somatostatin analogs, molecularly "targeted" therapies, and cytotoxic chemotherapy may be beneficial in controlling tumor growth. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p>In patients with limited metastases, however, local options can also be considered. The following sections will discuss local treatment options to control symptoms and tumor growth. Systemic options are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="headingAnchor" id="H330046143"><span class="h1">OVERVIEW OF THE APPROACH TO LOCAL TREATMENT</span><span class="headingEndMark"> — </span>For initial management of patients with hepatic metastases from gastrointestinal or pancreatic NETs in whom complete resection is possible, surgery is appropriate in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, particularly for low-volume or symptomatic disease and low-grade tumors. The benefit of surgical debulking in patients with incompletely resectable metastatic NETs is controversial and not universally accepted. (See <a class="local">'Surgical resection'</a> below.)</p><p>Another point of controversy is whether the primary site should be resected in patients with metastatic disease. For most malignancies, there is little rationale to resect the primary site when widespread, unresectable metastases are present. In patients with NETs, however, resection of the primary may be beneficial if the primary site is causing symptoms, even in the setting of metastatic disease, given the sometimes prolonged survival of such patients. Additionally, if the primary and liver metastases are both amenable to potentially curative resection, surgery should be performed. On the other hand, the benefit of resecting asymptomatic small bowel primary sites in patients with unresectable metastatic disease has not been clearly established. (See <a class="local">'Management of the primary tumor in patients with metastatic disease'</a> below.)</p><p>The role of ablation (radiofrequency ablation [RFA], cryoablation, microwave ablation) in the therapeutic management of small (&lt;3 cm) neuroendocrine liver metastases, particularly in patients who are eligible for resection, is undefined. Because the majority of patients present with multifocal and bilateral disease, ablation is most often used as an adjunct to surgical resection to allow local treatment of all disease when major hepatectomy alone might compromise residual liver function. (See <a class="local">'Ablation'</a> below.)</p><p>For symptomatic patients with hepatic-predominant, unresectable gastrointestinal or pancreatic NETs, transarterial therapy with hepatic arterial embolization, chemoembolization, or radioembolization is a potential alternative to medical therapy alone for symptom palliation. While many studies demonstrate successful control of symptoms related to hormone secretion or tumor bulk, survival benefits from transarterial therapy are less clear. (See <a class="local">'Hepatic arterial embolization'</a> below.)</p><p>Orthotopic liver transplantation is not currently a standard option for unresectable neuroendocrine liver metastases, and further investigation is needed to evaluate its benefits for patients with metastatic gastrointestinal and pancreatic NETs. (See <a class="local">'Liver transplantation'</a> below.)</p><p class="headingAnchor" id="H691398"><span class="h1">HEPATIC-PREDOMINANT METASTATIC DISEASE</span><span class="headingEndMark"> — </span>The majority of patients with advanced gastroenteropancreatic NETs have liver metastases. How to best manage patients with liver metastases from NETs is a complex issue requiring a multidisciplinary team approach, taking into account factors such as the extent and biology of disease, presence of tumor-related symptoms, and patient-related factors (such as age and performance status). The role of primary tumor resection in patients with metastatic disease is also discussed below. (See <a class="local">'Management of the primary tumor in patients with metastatic disease'</a> below.)</p><p class="headingAnchor" id="H691406"><span class="h2">Surgical resection</span><span class="headingEndMark"> — </span>For patients with liver metastases from a well-differentiated gastroenteropancreatic NET, surgical resection is an option in the absence of diffuse bilobar involvement, compromised liver function, or extrahepatic metastases. The presence of poorly differentiated neuroendocrine carcinoma is also usually a contraindication to resection. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Poorly differentiated NEC'</a>.)</p><p>Resection of neuroendocrine liver metastases via anatomic hepatectomy or multiple nonanatomic "wedge" resections can be performed even with bilobar involvement, provided sufficient functional hepatic reserve is preserved, typically over 20 percent of total liver volume and the presence of two contiguous preserved liver segments. The ability of the liver to undergo compensatory hypertrophy is decreased by cirrhosis, hepatitis, or steatosis related to obesity.</p><p>A surgical approach to hepatic-predominant disease has traditionally been advised given the limited availability of systemic therapy and the relatively indolent nature of disease. Historical recommendations have supported resection if at least 90 percent of the tumor can be feasibly removed [<a href="#rid3">3</a>]. However, the precise method of measuring 90 percent debulking is not defined, and the precise amount of tumor burden that must be treated for benefit remains unclear. Furthermore, randomized studies comparing hepatic resection versus a nonsurgical approach have not been performed. Finally, the indolent nature of the disease and the potential for selection bias have complicated the assessment of the efficacy of a surgical approach to hepatic-predominant disease. Nonetheless, the long-term survival and symptomatic improvement reported in select populations of patients undergoing hepatic resection of neuroendocrine liver metastases compare favorably with outcomes with other management approaches for advanced NETs  (<a class="graphic graphic_table graphicRef97744" href="/d/graphic/97744.html" rel="external">table 2</a>). A few of the largest series are described in detail:</p><p class="bulletIndent1"><span class="glyph">●</span>A large, early, single-institution series included 170 patients undergoing liver resection over a 20-year period [<a href="#rid4">4</a>]. Metastases were bilateral in the majority of patients, and most had hormonal symptoms. Symptom control was achieved in 96 percent of patients who presented with symptoms related to a functioning tumor; five-year symptom recurrence was 59 percent. Overall survival in the group was 61 and 35 percent at 5 and 10 years, respectively, with a median survival of 81 months. These outcomes compare favorably with historical controls [<a href="#rid5">5,6</a>]. Of note, recurrence rates were 84 and 95 percent at 5 and 10 years, respectively. Although nearly all patients developed a disease recurrence, surgery appeared to offer significant improvements in expected survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others report a lower rate of disease recurrence after hepatic resection, at least at five years [<a href="#rid7">7-10</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A second series of 144 patients undergoing resection with or without ablation for neuroendocrine liver metastases over a 30-year period at a single institution described a median overall survival of 9.6 years, with 5- and 10-year survivals of 77 and 50 percent, respectively [<a href="#rid8">8</a>]. While nearly 50 percent of all patients developed a recurrence of liver disease, most were able to have further local treatment with repeat resection or ablation. The authors acknowledge the selected nature of the patients undergoing surgical resection, as this number represented only 25 percent of the patients with stage IV NETs seen at that institution in the same time frame.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The largest published multi-institutional series of patients undergoing surgery for neuroendocrine liver metastases included 376 patients treated over a 24-year period across 10 hepatobiliary referral centers [<a href="#rid7">7</a>]. Most presented with bilobar disease, extrahepatic disease was present in 9 percent, and 22 percent of procedures included ablation as a component of the intervention. In the entire cohort, the disease-free survival rate at five years was 46 percent; overall survival was not reported. However, there was a tail to the disease-free survival curve beyond 10 years, suggesting that approximately 35 to 40 percent did not recur during this time frame. In multivariate analysis, the type of NET (pancreatic nonfunctional versus other), grade of tumor differentiation (moderately/poorly versus well), and extent of liver involvement were the only independent predictors of inferior disease-free survival.</p><p></p><p>Despite the apparent benefit of surgical resection in terms of symptom palliation and potentially increased survival, most series share a high recurrence rate, even with complete resection and microscopically negative margins. The high rate of intrahepatic recurrence is likely related to an underestimation of the true extent of disease burden with preoperative cross-sectional imaging. In a study comparing preoperative radiology findings with the pathologic review of resected neuroendocrine liver metastases, the extent of disease was underestimated by up to 50 percent, with many additional metastases &lt;2 mm identified in the pathologic specimen that had not been visualized on preoperative imaging [<a href="#rid9">9</a>].</p><p>While surgical resection may benefit highly selected patients, the potential for selection bias in these series and the lack of randomized data have made it difficult to assess the long-term benefits of this approach as compared with less invasive treatment strategies. One report of a large prospective database of 649 patients with neuroendocrine liver metastases who were followed for a median follow-up of 44 months suggested that hepatic resection was associated with a highly favorable overall survival (90 percent at five years) compared with other local modalities, such as radiofrequency ablation (RFA; 84 percent) and chemoembolization (55 percent), but the potential for selection bias (ie, that surgery was only offered to those patients who had an inherently better tumor biology) complicates interpretation of the results [<a href="#rid10">10</a>].</p><p>Some authors have attempted to address confounding factors by using propensity index modeling to identify patients with common characteristics for comparative analyses [<a href="#rid11">11,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>As an example, one report compared outcomes in a series of 339 patients with neuroendocrine liver metastases undergoing surgical therapy versus 414 patients with neuroendocrine liver metastases undergoing intra-arterial therapy (IAT) [<a href="#rid11">11</a>]. Patients undergoing IAT had more hormonally functioning tumors, a greater proportion of tumors with synchronous presentation of liver metastases, more extrahepatic metastases, more bilateral disease, and a greater extent of hepatic involvement, and they less frequently had their primary tumor resected. In the unadjusted analysis, median and five-year survival were, not surprisingly, significantly better for patients undergoing surgery as compared with IAT. Propensity score matching was used to identify a group of patients with balanced clinicopathologic characteristics who were most likely to have been considered for either treatment. While survival was significantly better in the surgical group in the unadjusted analysis, the propensity-adjusted analysis suggested that surgery was associated with superior outcomes in patients with a low (&lt;25 percent) hepatic disease burden and in those who were symptomatic and had &gt;25 percent hepatic tumor involvement. There was no treatment-related difference in long-term outcome in asymptomatic patients with &gt;25 percent hepatic tumor involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar statistical approach was applied to an analysis of 376 patients with neuroendocrine liver metastases from small intestinal NETs [<a href="#rid12">12</a>]. In this series, 103 patients undergoing hepatectomy or ablation were compared with 273 patients treated nonsurgically. Patients selected for surgery were less likely to have symptomatic disease, were less likely to have residual or unresected extrahepatic disease or nodal metastases, and had lower overall disease burden and lower grade tumors. In an unadjusted comparison, five-year overall survival was 78 percent after surgery or ablation versus 56 percent in controls. To account for selection bias, propensity score matching identified two groups, each with 72 patients, without significant differences in baseline features. The five-year overall survival was 74 percent in both the matched surgery/ablation and nonsurgically treated groups, suggesting that surgery may not be clearly superior to nonoperative therapy for many patients.</p><p></p><p>Taken together, these data support the view that although intrahepatic disease progression and recurrence rates are high, resection of neuroendocrine liver metastases can provide symptom control and has been associated with favorable long-term survival, with 10-year survival rates approaching 50 to 60 percent in some series [<a href="#rid10">10</a>]. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend consideration of cytoreductive surgery or ablative therapy if near-complete treatment of tumor burden can be achieved [<a href="#rid13">13</a>].</p><p>For patients with carcinoid syndrome, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> should be readily available during any surgical procedure. (See <a class="local">'Prevention and management of carcinoid crisis'</a> below.)</p><p>Appropriate preoperative assessment and complications of hepatic resection are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15094.html" rel="external">"Overview of hepatic resection"</a>.)</p><p class="headingAnchor" id="H691441"><span class="h2">Nonsurgical liver-directed therapy</span></p><p class="headingAnchor" id="H178294546"><span class="h3">Ablation</span><span class="headingEndMark"> — </span>Ablation can be used as a primary treatment modality for neuroendocrine liver metastases or as an adjunct to surgical resection. The most commonly used ablation technique is RFA, but other modalities, including cryoablation and microwave ablation, can be utilized. These procedures, which can be performed percutaneously, laparoscopically, or at the time of laparotomy, are less morbid than either hepatic resection or hepatic arterial embolization. However, because the zone of ablation is limited, ablative techniques may be applicable only to smaller lesions (typically ≤3 cm).</p><p>Many published reports of tumor ablation are small case studies of fewer than 40 patients [<a href="#rid14">14-19</a>]. The largest published series examining ablation for neuroendocrine liver metastases included 89 patients undergoing laparoscopic RFA [<a href="#rid20">20</a>]. The mean number of lesions treated per patient was six (range 1 to 16), with a mean lesion size of 3.6 cm (range 1 to 10 cm). There was one postoperative death and a 6 percent perioperative morbidity rate, most frequently related to hemorrhage. Among patients with hormonal symptoms (44 percent), significant or complete symptom relief occurred in 73 percent of patients when assessed one week postprocedure, and relief was sustained for a median of 14 months. At a median follow-up of 30 months, the median disease-free survival after the first RFA treatment was 16 months, with an overall survival of six years. Twenty-two percent of patients developed a local liver recurrence, and 59 percent developed extrahepatic disease. Multimodality treatment subsequently was used to control disease, including <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (30 percent), repeat RFA (27 percent), chemoembolization (7 percent), and chemotherapy (18 percent).</p><p>The role of ablation in the therapeutic management of small neuroendocrine liver metastases, particularly in patients who are eligible for resection, is undefined. Because the majority of patients present with multifocal and bilateral disease, a primary role for ablation may be as an adjunct to surgical resection to allow local treatment of all disease when major hepatectomy alone might compromise residual liver function. Ablation may also be particularly useful for patients with an intrahepatic disease recurrence in whom surgical options are limited due to prior hepatectomy. The combination of resection and ablation is a well-described strategy for a variety of malignancies. In the series reported by Mayo et al, 66 of 339 patients (19 percent) undergoing liver-directed therapy underwent a combination of resection and ablation at the initial surgical attempt. A smaller number of patients underwent a second liver-directed procedure (n = 46), with increasing use of ablation alone (7 of 46; 15.2 percent) or resection plus ablation (17 of 46; 37 percent) during the second procedure [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H691449"><span class="h3">Hepatic arterial embolization</span><span class="headingEndMark"> — </span>We suggest hepatic arterial embolization, chemoembolization, or radioembolization as an alternative to medical therapy alone as a palliative technique for symptomatic patients with hepatic-predominant unresectable gastrointestinal or pancreatic NETs.</p><p>Hepatic arterial embolization is frequently applied as a palliative technique in patients with a hepatic-predominant metastatic NET who are not candidates for surgical resection. It is based on the principle that tumors in the liver derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive most of their blood supply from the portal vein.</p><p>Embolization can be performed via the infusion of gel foam powder into the hepatic artery through an angiography catheter (bland embolization) or in conjunction with chemotherapy (ie, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, or <a class="drug drug_general" data-topicid="9949" href="/d/drug information/9949.html" rel="external">streptozocin</a>, or drug-eluting beads) administered via the hepatic artery (chemoembolization). A third embolization technique uses radioactive isotopes (eg, yttrium-90 [90-Y]) that are tagged to glass or resin microspheres and delivered selectively to the tumor via the hepatic artery.</p><p class="headingAnchor" id="H5473965"><span class="h4">Technique and outcomes</span><span class="headingEndMark"> — </span>In the absence of randomized trials, we consider any of the three techniques (bland embolization, chemoembolization, or radioembolization) to be a reasonable approach for the palliation of patients with NETs and hepatic-predominant disease who are not candidates for surgical resection.</p><p>In uncontrolled studies, efficacy appears to be similar for the three techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>The response rates associated with all of these techniques, as measured by either decreased hormone secretion, symptomatic benefit, or radiographic regression, are generally over 50 percent, even among patients with massive hepatic tumor burden [<a href="#rid22">22-38</a>]. While many studies demonstrate symptom control, survival benefits from transarterial therapy are less clear [<a href="#rid25">25,27,39-43</a>]. Comparisons between studies and between methods of transarterial therapy are frustrated by the heterogeneity of inclusion criteria and the wide range of techniques used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A year 2015 systematic review of 18 studies conducted by a multidisciplinary panel of experts examined the clinical efficacy and safety of hepatic arterial chemoembolization, bland embolization, and radioembolization for patients with neuroendocrine liver metastases [<a href="#rid44">44</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although patient heterogeneity and differences in embolic technique make comparisons between studies and modalities difficult, similar tumor response rates, survival, and symptom palliation were observed with all techniques.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 11 studies examining bland embolization or chemoembolization, objective radiologic response rates ranged from 11 to 100 percent. Median survival durations ranged between 18 and 80 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In seven studies of radioembolization, objective radiologic response rates ranged from 22 to 71 percent. Reported median survival durations ranged between 22 and 70 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one of the largest reports of 81 patients undergoing bland embolization or chemoembolization for a gastrointestinal NET, the median response duration was 17 months, and progression-free survival (PFS) rates at one, two, and three years were 75, 35, and 11 percent [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">A second series of 69 patients with a gastrointestinal NET and 54 with a pancreatic NET suggested better results for gastrointestinal NETs (response rate 67 versus 35 percent, median PFS 23 versus 16 months, and median overall survival 34 versus 23 months) [<a href="#rid34">34</a>]. The addition of chemotherapy to hepatic arterial embolization seemed to benefit pancreatic but not gastrointestinal NETs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experience with 90-Y radioembolization in metastatic NETs has been growing [<a href="#rid29">29-31,35,36,45</a>]. In the largest series, reported by Kennedy et al, of 148 patients with unresectable liver metastases, 64 percent had an objective response [<a href="#rid29">29</a>]. Fatigue (7 percent) was the most common side effect.</p><p></p><p class="bulletIndent1">As with other techniques, radioembolization has been reported to reduce symptoms in approximately one-half of patients with functioning tumors [<a href="#rid31">31,35</a>]. A single case report describes control of refractory hypoglycemia for three months following radioembolization of a metastatic malignant insulinoma [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">Several publications have evaluated the incidence of hepatic toxicity with 90-Y radioembolization in patients with neuroendocrine liver metastases. Cases of radiation-induced hepatic fibrosis and cirrhosis developing over the course of several years have been reported [<a href="#rid47">47-49</a>].</p><p></p><p class="bulletIndent1">Retrospective comparative studies of 90-Y radioembolization versus transarterial chemoembolization have come to variable conclusions as to whether either approach is superior, at least in part due to heterogeneous patient populations [<a href="#rid50">50-53</a>]. Randomized trials are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concern has been raised as to the high incidence of biliary injury with transarterial chemoembolization using drug-eluting beads [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Information is expected from the RETNET (Randomized Embolization Trial for NeuroEndocrine Tumor metastases to the liver) trial, a prospective, multicenter, randomized, controlled trial designed to determine the optimal embolotherapy technique for NET liver metastases (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02724540&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPN3LuJK518y6ePWMiuZMzJOtej1KknabYGEeqDixZDXmw%3D%3D&amp;TOPIC_ID=16105" target="_blank">NCT02724540</a>). In this trial, patients with progressive or symptomatic unresectable neuroendocrine liver metastases will be randomized to bland embolization or transarterial chemoembolization. An arm of this trial evaluating transarterial chemoembolization using drug-eluting beads has closed due to concerns regarding hepatic toxicity.</p><p></p><p>Regardless of the approach that is chosen, appropriate patient selection is important to minimize treatment- and disease-related adverse effects, which can include pain, nausea, fever, fatigue, and biochemical abnormalities (elevated liver enzymes) [<a href="#rid55">55</a>]. Importantly, the toxicity and safety of 90-Y radioembolization for patients who have undergone or may be candidates for future peptide receptor radionuclide therapy have not been established. (See  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Lutetium-177 dotatate'</a> and  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Lutetium Lu-177 dotatate'</a>.) </p><p>Contraindications and complications of transarterial therapies, which are similar whether the approach is being used for NETs or for hepatocellular cancer, are presented elsewhere. However, in contrast to hepatocellular cancer, the presence of extrahepatic disease is not a contraindication to transarterial embolization for NETs, particularly for highly symptomatic patients [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'Radioembolization'</a>.)</p><p>Prophylaxis for carcinoid crisis should also be considered prior to embolization in patients with carcinoid syndrome [<a href="#rid56">56</a>]. (See <a class="local">'Prevention and management of carcinoid crisis'</a> below.)</p><p class="headingAnchor" id="H178295652"><span class="h2">Liver transplantation</span><span class="headingEndMark"> — </span>Orthotopic liver transplantation (OLT) is not currently a standard option for unresectable neuroendocrine liver metastases, and further investigation is needed to evaluate its benefits.</p><p>The number of patients with liver-isolated metastatic disease in whom OLT has been attempted is relatively small, and the role of OLT in patients with metastatic NETs is not yet established and remains controversial [<a href="#rid57">57-62</a>]. One of the largest reported series included 213 patients who underwent OLT for NETs in 35 centers in 11 European countries between 1982 and 2009 [<a href="#rid63">63</a>]. Perioperative mortality within three months of transplantation was 10 percent. At a median follow-up of 56 months, the one-, three-, and five-year overall survival rates were 81, 65, and 52 percent, respectively, while the corresponding disease-free survival rates were 65, 40, and 30 percent.</p><p>In a report from the United Network for Organ Sharing (UNOS) database, 150 transplants were performed for metastatic NETs between 1988 and 2008 [<a href="#rid62">62</a>], including 51 for gastrointestinal NETs, 29 for pancreatic NETs, and 70 for unspecified NETs. The one-, three-, and five-year survival rates for the 137 patients undergoing isolated OLT were 81, 65, and 49 percent, respectively, and there were no differences based on site of tumor origin.</p><p>While long-term recurrence-free survival may be obtained in a minority of patients, the majority of those undergoing OLT for metastatic NETs ultimately develop recurrent disease [<a href="#rid57">57,64-66</a>]. Strict selection of patients for transplantation is therefore critical. In a systematic literature review of liver transplantation for hepatic metastases from NETs (64 studies, 57 of which were single-center reports), recurrence rates ranged from 33 to 57 percent [<a href="#rid66">66</a>].</p><p>The limited availability of donor organs in many regions has also limited the widespread use of this procedure. In the United States, where allocation of donor organs for transplantation is based on the Model for End-Stage Liver Disease (MELD) as proscribed by the Organ Procurement Transplantation Network (OPTN)/UNOS, there are no MELD exception points for NETs like there are for hepatocellular cancer. (See  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Requirements for listing and management while on the wait list'</a>.)</p><p>However, guidance on MELD exception review is available from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fmedia%2F2175%2Fliver_boardreport_guidance_201706.pdf&amp;token=dk0pChGib7lllVfLFBOyd%2Fj2PX%2F73zF0IPHjodwyhIjPl1vrhGHgo9KOc58hsQOXXAyW2DLVCNxCyLkybRp3GPIfWd7vio%2BbRjVXAN%2BUcyE%3D&amp;TOPIC_ID=16105" target="_blank">OPTN for patients with liver metastases from NETs</a>, which is intended to be used by regional review boards to evaluate case requests for liver transplantation in these patients in order to promote consistent review of these patients throughout the country.</p><p class="headingAnchor" id="H178295679"><span class="h1">MANAGEMENT OF THE PRIMARY TUMOR IN PATIENTS WITH METASTATIC DISEASE</span></p><p class="headingAnchor" id="H337349677"><span class="h2">Small bowel primaries</span><span class="headingEndMark"> — </span>We suggest resection for symptomatic small bowel primary sites and for asymptomatic primaries if both the primary site and liver metastases are amenable to complete or near-complete resection as noted above. The benefit of resecting asymptomatic small bowel primary sites in patients with unresectable metastatic disease has not been clearly established, and we suggest not pursuing this approach.</p><p>For most malignancies, there is little rationale to resect the primary site when widespread, unresectable metastases are present. In patients with small bowel NETs, however, resection of the primary may be beneficial if the primary site is causing symptoms, even in the setting of metastatic disease, given the sometimes prolonged survival of such patients. Additionally, if the primary and liver metastases are both amenable to potentially curative resection, surgery should be performed [<a href="#rid4">4,67,68</a>].</p><p>Small bowel NETs are often associated with desmoplasia and fibrosis, which can result in intermittent small bowel obstruction and, in some cases, bowel ischemia [<a href="#rid69">69,70</a>]. Surgical resection of the primary should therefore be considered in patients experiencing intermittent obstruction or abdominal discomfort thought to be related to the primary tumor, even in the presence of metastatic disease [<a href="#rid71">71</a>]. Mesenteric angioplasty or stenting could be an option in selected patients, although experience with this approach is limited [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/2563.html" rel="external">"Chronic mesenteric ischemia", section on 'Revascularization'</a>.)</p><p>While some have also advocated the routine resection of asymptomatic small bowel primary tumors in patients with unresectable metastatic disease, this practice remains controversial. Guidelines on the surgical management of small bowel NETs are available from the North American Neuroendocrine Tumor Society (NANETS), the European Neuroendocrine Tumor Society (ENETS), the National Comprehensive Cancer Network (NCCN), and the European Society for Medical Oncology (ESMO):</p><p class="bulletIndent1"><span class="glyph">●</span>The NANETS guidelines recommend that resection of the primary tumor be considered, when feasible, to relieve symptoms, to avoid future symptoms, and for a potential survival advantage [<a href="#rid72">72</a>]. However, they also point out that the benefits of removing an asymptomatic primary tumor are controversial, that clinical factors, including the extent of metastatic disease, need to be considered, and that the risks of resection need to be weighed against the potential benefits [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ENETS guidelines do not provide specific recommendations regarding resection of an asymptomatic primary small intestinal NET in the presence of unresectable liver metastases, but they do state that there may be a role for resection to prevent later complications and acknowledge that the lack of prospective trials does not allow firm conclusions on any potential survival benefit [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NCCN recommends that both the primary and metastases be resected if both are resectable and that resection also be considered for symptomatic primary tumors in the setting of metastatic disease, but provides no recommendation for patients with asymptomatic primary tumors and categorically unresectable metastatic disease [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ESMO guidelines also endorse palliative resection of primary small intestinal NETs in advanced disease to prevent complications related to bowel obstruction or intestinal ischemia, also noting that there are contradictory data on the survival benefit of this approach [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H1999845226"><span class="h3">Does resection prolong survival?</span><span class="headingEndMark"> — </span>The available data on the survival benefits of resecting an asymptomatic primary are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>At least two systematic reviews have concluded that there is at least a trend toward longer survival in patients who undergo resection of the primary tumor despite the presence of metastatic disease [<a href="#rid78">78,79</a>]. However, the retrospective nature of these studies makes the data difficult to interpret given the high potential for selection bias in patients taken to surgery compared with those who were not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A large retrospective cohort of 4076 patients with metastatic midgut NETs derived from the National Cancer Database also concluded that there was a survival benefit for resection of the primary tumor (hazard ratio for death for those with primary tumor resection versus without 0.63, 95% CI 0.51-0.78) [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, a survival benefit for primary tumor resection could not be shown in a cohort study from Sweden, which examined outcomes among 161 patients with metastatic small bowel NETs without abdominal symptoms who had prophylactic surgery within six months of diagnosis combined with oncologic treatment, compared with 202 similar patients who underwent nonsurgical treatment or delayed surgery as needed in combination with oncologic treatment [<a href="#rid81">81</a>]. Prophylactic primary tumor resection conferred no survival benefit compared with delayed surgery as needed, and patients undergoing prophylactic surgery needed more reoperations for intestinal obstruction compared with delayed surgery as needed (14 versus 3 percent).</p><p></p><p class="headingAnchor" id="H4132098654"><span class="h2">Pancreatic neuroendocrine tumors</span><span class="headingEndMark"> — </span>The benefit of resecting the primary tumor in patients with metastatic nonfunctioning pancreatic NETs is also controversial. In contrast to small bowel primaries, in most series, removal of the primary tumor has been associated with longer survival, even in the setting of unresectable metastatic disease. However, all of the experience comes from retrospective analyses, and it remains possible that the perceived survival benefit is the result of selection bias. The issue of resection of the primary tumor in patients with nonfunctioning pancreatic NETs is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15045.html" rel="external">"Surgical resection of sporadic pancreatic neuroendocrine tumors", section on 'Candidates for resection'</a> and  <a class="medical medical_review" href="/d/html/15045.html" rel="external">"Surgical resection of sporadic pancreatic neuroendocrine tumors", section on 'Nonfunctional'</a>.)</p><p class="headingAnchor" id="H25195080"><span class="h1">PREVENTION AND MANAGEMENT OF CARCINOID CRISIS</span><span class="headingEndMark"> — </span>Carcinoid crisis is a life-threatening form of carcinoid syndrome that may be triggered by tumor manipulation (biopsy, palpation at the bedside or during surgery) or by anesthesia. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy, mostly in patients with extensive tumor bulk.</p><p>Carcinoid crisis results from the release of an overwhelming amount of biologically active compounds from the tumor  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 3</a>). In addition to hemodynamic instability, symptoms include flushing, diarrhea, tachycardia, arrhythmias, bronchospasm, and altered mental status.</p><p>Recent studies have questioned the routine need for prophylactic preoperative <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in all patients with metastatic neuroendocrine tumors, particularly for those who are already receiving long-acting somatostatin analogs or do not have carcinoid syndrome. If prophylactic octreotide is not administered, it should be available intraoperatively for emergent intravenous use for patients with carcinoid syndrome who develop hemodynamic instability concerning for carcinoid crisis.</p><p class="headingAnchor" id="H2605440121"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H25195131"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For initial management of patients with hepatic metastases from well-differentiated gastrointestinal or pancreatic neuroendocrine tumors (NETs) that can be completely resected, we suggest resection rather than medical therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Resection is an appropriate treatment for liver metastases in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, particularly for low-volume or symptomatic disease and low-grade tumors. The benefits of surgical debulking in patients with incompletely resectable metastatic gastrointestinal or pancreatic NETs remain controversial, and this should be considered an investigational approach. (See <a class="local">'Surgical resection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest resection for symptomatic small bowel primary sites and for asymptomatic primaries if both the primary site and liver metastases are amenable to potentially curative resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The benefit of resecting asymptomatic small bowel primary sites in patients with unresectable metastatic disease has not been clearly established, and we suggest not pursuing this approach (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management of the primary tumor in patients with metastatic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent studies have questioned the routine need for prophylactic preoperative <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in all patients with metastatic neuroendocrine tumors, particularly for those who are already receiving long-acting somatostatin analogs or do not have carcinoid syndrome. If prophylactic octreotide is not administered, it should be available intraoperatively for emergent intravenous use for patients with carcinoid syndrome who develop hemodynamic instability concerning for carcinoid crisis. This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome", section on 'Carcinoid crisis: prevention and management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orthotopic liver transplantation (OLT) is not currently a standard option for unresectable neuroendocrine liver metastases, and further investigation is needed to evaluate its benefits for patients with metastatic gastrointestinal and pancreatic NETs. (See <a class="local">'Liver transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest hepatic arterial embolization, chemoembolization, or radioembolization as an alternative to medical therapy alone as a palliative technique for symptomatic patients with hepatic-predominant unresectable gastrointestinal or pancreatic NETs (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The toxicity and safety of yttrium-90 (90-Y) radioembolization for patients who have undergone or may be candidates for future peptide receptor radionuclide therapy have not been established. (See <a class="local">'Hepatic arterial embolization'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a class="nounderline abstract_t">Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006; 140:891.</a></li><li><a class="nounderline abstract_t">Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29.</a></li><li><a class="nounderline abstract_t">Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432.</a></li><li><a class="nounderline abstract_t">Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187:88.</a></li><li><a class="nounderline abstract_t">Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. J Surg Oncol 2017; 115:687.</a></li><li><a class="nounderline abstract_t">Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12:427.</a></li><li><a class="nounderline abstract_t">Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think... Ann Surg 2010; 251:307.</a></li><li><a class="nounderline abstract_t">Fairweather M, Swanson R, Wang J, et al. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol 2017; 24:2319.</a></li><li><a class="nounderline abstract_t">Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011; 18:3657.</a></li><li><a class="nounderline abstract_t">Norlén O, Stålberg P, Zedenius J, Hellman P. Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 2013; 100:1505.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30:435.</a></li><li><a class="nounderline abstract_t">Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001; 95:8.</a></li><li><a class="nounderline abstract_t">Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26:1052.</a></li><li><a class="nounderline abstract_t">Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26:985.</a></li><li><a class="nounderline abstract_t">Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142:10.</a></li><li><a class="nounderline abstract_t">Mazzaglia PJ, Berber E, Siperstein AE. Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver. Curr Treat Options Oncol 2007; 8:322.</a></li><li><a class="nounderline abstract_t">Akyildiz HY, Mitchell J, Milas M, et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148:1288.</a></li><li><a class="nounderline abstract_t">Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17:3129.</a></li><li><a class="nounderline abstract_t">Swärd C, Johanson V, Nieveen van Dijkum E, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96:517.</a></li><li><a class="nounderline abstract_t">Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624.</a></li><li><a class="nounderline abstract_t">Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293.</a></li><li><a class="nounderline abstract_t">Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144:885.</a></li><li><a class="nounderline abstract_t">Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175:408.</a></li><li><a class="nounderline abstract_t">Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180:1379.</a></li><li><a class="nounderline abstract_t">de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008; 19:855.</a></li><li><a class="nounderline abstract_t">Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31:271.</a></li><li><a class="nounderline abstract_t">Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247:1029.</a></li><li><a class="nounderline abstract_t">King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921.</a></li><li><a class="nounderline abstract_t">Gaur SK, Friese JL, Sadow CA, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34:566.</a></li><li><a class="nounderline abstract_t">Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol 2013; 20:1114.</a></li><li><a class="nounderline abstract_t">Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590.</a></li><li><a class="nounderline abstract_t">Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537.</a></li><li><a class="nounderline abstract_t">Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83:887.</a></li><li><a class="nounderline abstract_t">Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261.</a></li><li><a class="nounderline abstract_t">Kitano M, Davidson GW, Shirley LA, et al. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk? Ann Surg Oncol 2016; 23:4008.</a></li><li><a class="nounderline abstract_t">Vogl TJ, Gruber T, Naguib NN, et al. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol 2009; 193:941.</a></li><li><a class="nounderline abstract_t">Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011; 28 Suppl 1:S286.</a></li><li><a class="nounderline abstract_t">Pitt SC, Knuth J, Keily JM, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 2008; 12:1951.</a></li><li><a class="nounderline abstract_t">Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18:847.</a></li><li><a class="nounderline abstract_t">Schell SR, Camp ER, Caridi JG, Hawkins IF Jr. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002; 6:664.</a></li><li><a class="nounderline abstract_t">Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 2015; 17:29.</a></li><li><a class="nounderline abstract_t">Benson AB 3rd, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 2013; 49:3122.</a></li><li><a class="nounderline abstract_t">Chandra P, Yarandi SS, Khazai N, et al. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci 2010; 340:414.</a></li><li><a class="nounderline abstract_t">Su YK, Mackey RV, Riaz A, et al. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. J Vasc Interv Radiol 2017; 28:1520.</a></li><li><a class="nounderline abstract_t">Loree JM, Hiruki T, Kennecke HF. Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases. Case Rep Oncol 2016; 9:76.</a></li><li><a class="nounderline abstract_t">Zuckerman DA, Kennard RF, Roy A, et al. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience. J Gastrointest Oncol 2019; 10:118.</a></li><li><a class="nounderline abstract_t">Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol 2017; 27:4995.</a></li><li><a class="nounderline abstract_t">Egger ME, Armstrong E, Martin RC 2nd, et al. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg 2020; 230:363.</a></li><li><a class="nounderline abstract_t">Ngo L, Elnahla A, Attia AS, et al. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. Ann Surg Oncol 2021; 28:1950.</a></li><li><a class="nounderline abstract_t">Chen JX, Rose S, White SB, et al. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Cardiovasc Intervent Radiol 2017; 40:69.</a></li><li><a class="nounderline abstract_t">Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013; 36:449.</a></li><li><a class="nounderline abstract_t">Lewis MA, Jaramillo S, Roberts L, et al. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012; 17:725.</a></li><li><a class="nounderline abstract_t">Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999; 19:399.</a></li><li><a class="nounderline abstract_t">Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225:355.</a></li><li><a class="nounderline abstract_t">Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225:347.</a></li><li><a class="nounderline abstract_t">van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl 2006; 12:448.</a></li><li><a class="nounderline abstract_t">Marín C, Robles R, Fernández JA, et al. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc 2007; 39:2302.</a></li><li><a class="nounderline abstract_t">Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13:327.</a></li><li><a class="nounderline abstract_t">Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146:953.</a></li><li><a class="nounderline abstract_t">Le Treut YP, Grégoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257:807.</a></li><li><a class="nounderline abstract_t">Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011; 91:575.</a></li><li><a class="nounderline abstract_t">Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8:208.</a></li><li><a class="nounderline abstract_t">Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery 2017; 162:525.</a></li><li><a class="nounderline abstract_t">Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol 2012; 19:4270.</a></li><li><a class="nounderline abstract_t">Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008; 113:126.</a></li><li><a class="nounderline abstract_t">Daskalakis K, Karakatsanis A, Stålberg P, et al. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg 2017; 104:69.</a></li><li><a class="nounderline abstract_t">Laskaratos FM, Rombouts K, Caplin M, et al. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer 2017; 123:4770.</a></li><li><a class="nounderline abstract_t">Gulec SA, Mountcastle TS, Frey D, et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 2002; 68:667.</a></li><li><a class="nounderline abstract_t">Howe JR, Cardona K, Fraker DL, et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017; 46:715.</a></li><li><a class="nounderline abstract_t">Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39:753.</a></li><li><a class="nounderline abstract_t">Partelli S, Bartsch DK, Capdevila J, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology 2017; 105:255.</a></li><li><a class="nounderline abstract_t">Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/#site (Accessed on July 28, 2020).</li><li><a class="nounderline abstract_t">Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:844.</a></li><li><a class="nounderline abstract_t">Capurso G, Rinzivillo M, Bettini R, et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 2012; 99:1480.</a></li><li><a class="nounderline abstract_t">Van Den Heede K, Chidambaram S, Van Slycke S, et al. Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis. Br J Surg 2022; 109:191.</a></li><li><a class="nounderline abstract_t">Polcz M, Schlegel C, Edwards GC, et al. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors. Ann Surg Oncol 2020; 27:2795.</a></li><li><a class="nounderline abstract_t">Daskalakis K, Karakatsanis A, Hessman O, et al. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. JAMA Oncol 2018; 4:183.</a></li></ol></div><div id="topicVersionRevision">Topic 16105 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188135" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12831921" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757381" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatic neuroendocrine metastases: does intervention alter outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660030" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146608" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuroendocrine liver metastasis: The chance to be cured after liver surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20662794" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term survival after surgical management of neuroendocrine hepatic metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010089" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think...</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28303430" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21681380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037573" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037573" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15759207" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120628" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Radiofrequency ablation treatment of refractory carcinoid hepatic metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12016482" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12016479" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17629995" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084730" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134563" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20585879" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384072" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840528" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040993" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600289" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704055" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503899" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525307" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520231" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21431978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23456380" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134179" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20205229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137020" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967136" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27393568" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770314" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107755" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18709512" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hepatic neuroendocrine metastases: chemo- or bland embolization?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17609443" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399054" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186181" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777743" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20724903" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673658" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933423" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30788167" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28677067" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032719" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33393019" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27738818" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722717" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511263" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194787" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chemoembolization of hepatic neoplasms: safety, complications, and when to worry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114793" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114792" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Liver transplantation for metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498656" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889171" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of liver transplantation in the management of unresectable neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318853" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844436" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532105" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200365" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15036197" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Liver transplantation for neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624178" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752376" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Synchronous resection of primary and liver metastases for neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18457323" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861745" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical signs of fibrosis in small intestinal neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112233" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neuroendocrine tumors and fibrosis: An unsolved mystery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12206599" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cytoreductive surgery in patients with advanced-stage carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609357" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664473" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28237989" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262080" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262080" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272208" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972490" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34941998" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32430752" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049611" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
